SCHEMBL3840652

SCHEMBL3840652

C=CCOc1cnc2ccc(OC)cc2n1

nearest known ligand 0.46

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
PDGFRB P09619 5/20 0.46
PDGFRA P16234 5/20 0.46
RAB9A P51151 3/20 0.46
NPC1 O15118 2/20 0.46
NPSR1 Q6W5P4 2/20 0.46
HTT P42858 1/20 0.46
RXFP1 Q9HBX9 1/20 0.46
ALDH1A1 P00352 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
LMNA P02545 2/20 0.45
MEN1 O00255 2/20 0.45
POLB P06746 2/20 0.45
KMT2A Q03164 2/20 0.45
KDM4E B2RXH2 1/20 0.45
NQO2 P16083 1/20 0.45
MAPT P10636 2/20 0.42
GAA P10253 1/20 0.42
CSF1R P07333 1/20 0.42
EGFR P00533 3/20 0.41
HPGDS O60760 3/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3841710 0.94 PDGFRB (0.46) PDGFRBPDGFRARAB9ANPC1NPSR1
SCHEMBL28035890 0.75 RAB9A (0.56) PDGFRBPDGFRARAB9ANPC1NPSR1
SCHEMBL27259808 0.74 HTT (0.60) PDGFRBPDGFRARAB9ANPC1NPSR1
SCHEMBL2169923 0.73 PDGFRB (0.42) PDGFRBPDGFRARAB9ANPC1NPSR1
SCHEMBL5355917 0.73 CA12 (0.55) RAB9ANPC1NPSR1ALDH1A1SMN1; SMN2
SCHEMBL28450170 0.72 ALDH1A1 (0.50) PDGFRBPDGFRARAB9ANPC1NPSR1
SCHEMBL622678 0.72 PDGFRB (0.48) PDGFRBPDGFRARAB9ANPC1NPSR1
SCHEMBL14970152 0.72 ALDH1A1 (0.56) PDGFRBPDGFRARAB9ANPC1ALDH1A1
SCHEMBL31432706 0.71 FLT3 (0.52) ALDH1A1SMN1; SMN2MEN1KMT2AKDM4E
SCHEMBL10272929 0.71 ALDH1A1 (0.51) PDGFRBPDGFRARAB9ANPC1HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2044077-B1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES GLAXO GROUP LTD (GB) 2016-10-05 EP disclosed
US-8071592-B2 Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones GLAXO GROUP LIMITED (GB) 2011-12-06 US disclosed
US-20090270374-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES GLAXO GROUP LIMITED (GB) 2009-10-29 US disclosed
EP-2044077-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES Glaxo Group Limited (GB) 2009-04-08 EP disclosed
EP-1992628-A1 Derivatives and analogs of N-ethylquinolones and N-ethylazaquinolones GLAXO GROUP LIMITED (GB) 2008-11-19 EP disclosed
WO-2008009700-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES GLAXO GROUP LIMITED (GB) 2008-01-24 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090270374-A1 DERIVATIVES AND ANALOGS OF N-ETHYLQUINOLONES AND N-ETHYLAZAQUINOLONES ETFA, NQO2, GNAQ PDGFRB 4008/4885PDGFRA 3448/4885RAB9A 797/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.